Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)

Details

Instance of

clinical trial

Start time

July 2020

End time

July 2023

Main subject

autoimmune hepatitis, hepatitis, hepatitis A

clinical trial phase

phase II clinical trial, phase III clinical trial

maximum age

65

minimum age

18

number of participants

210

research subject recruitment status

not yet recruiting

study type

interventional study

title

A Seamless Phase II/III 2-stage Design, Randomized, Double-Blind, Placebo Controlled, Trial of JKB-122 as an Adjunct Therapy to Prednisolone and Azathioprine in the Induction of Remission in Autoimmune Hepatitis (AIH)